A group of hospital systems are using the machine-learning model to guide decisions on who should be tested for high levels of lipoprotein(a).
If it can secure the funds, Oncolytics will advance the agent into a pivotal study, based on positive data from the Phase I BRACELET-1 trial.
At a thrombosis research center, an observational study is underway investigating the impact of numerous biomarkers on ...
Researchers reported at the ESMO Congress that 78 percent of patients responded to front-line treatment with Lumakras, ...
Within the registrational trial, investigators will compare a single dose of 4D-150 to treatment with standard anti-VEGF therapy.
The center will conduct research and advance precision medicines for diabetes, pediatric rare diseases, cancer, and Alzheimer's disease.
The bill's passage through the committee improves the rare pediatric disease priority review voucher program's chances of being reauthorized before it expires Sept. 30.
Researchers at the ESMO Congress presented data showing better responses on dual-checkpoint blockade in the biomarker-defined ...
The French firm has a lead metastatic colorectal cancer vaccine candidate headed for Phase I/IIA trials, in which it will explore ways of predicting response.
The firm, in the midst of a Phase III trial testing a cell therapy for heart failure, has demonstrated compliance with Nasdaq's equity rule.
The firms will collaborate on two lead programs and up to five future targets in other diseases, with NanoVation eligible for up to $600 million in payments from Novo Nordisk.
Experts noted, however, there is insufficient evidence to determine which commercially available KRAS G12C inhibitor is the ...